Royalty Pharma Analyst Price Targets

Royalty Pharma PLC

RPRXNASDAQ

Trade with Public

$60.30

-0.66-1.08%

Ult. Agg.: Oct 19, 11:18 AM

$60.44

-0.52-0.85%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Dividendi Confronta Opzioni Rapporto azionario

Royalty Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Royalty Pharma (RPRX).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$56Upside to Avg. PT-7.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$65→$67
Sep 8, 2026	TD Cowen	Michael Nedelcovych	PT Raise	Buy	$65→$68
Aug 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$58→$62
Jul 13, 2026	TD Cowen	Steve Scala	PT Raise	Buy	$50→$65
May 7, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$50→$66
May 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$50→$58
Apr 21, 2026	UBS	Ashwani Verma	PT Raise	Buy	$51→$57
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$61→$63
Jan 30, 2026	UBS	Ashwani Verma	Upgrade	Neutral→Buy	$38→$49
Jan 27, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$48→$50
Dec 11, 2025	TD Cowen	Steve Scala	PT Raise	Buy	$42→$45
Oct 10, 2025	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$55→$54
Sep 30, 2025	Goldman Sachs	Asad Haider	Initiate	Buy	$42
Jul 22, 2025	Citigroup	Geoff Meacham	PT Raise	Buy	$40→$42
Jul 10, 2025	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$51→$54
Oct 25, 2024	Citigroup	Andrew Baum	PT Cut	Buy	$60→$40
Aug 14, 2024	Goldman Sachs	Chris Shibutani	PT Raise	Buy	$50→$51
Jul 11, 2024	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$48→$51
Jun 3, 2024	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$28
Apr 12, 2024	B of A Securities	Geoff Meacham	PT Cut	Buy	$40→$38

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $65 to $67.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $65.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $66.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $50 to $58.

Benzinga Newsdesk

Royalty Pharma PLC

Royalty Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Royalty Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

People Also Watch

People Also Watch

Royalty Pharma PLC

Royalty Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

PROTD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

PROJP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

PROTD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

PROCitigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

PROJP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Royalty Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

PROTD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

PROJP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

PROTD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

PROCitigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

PROJP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

PRO
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $67

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62

PRO
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65

PRO
Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

PRO
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58